Abstract Library

#3292 Neuroendocrine differentiation of metastasised castrate-resistant prostate cancer patients referred for radioligand therapy with Lu-177 PSMA

Introduction: Neuroendocrine differentiation (NED) of metastasised castrate-resistant prostate cancer (mCRPC) is normally associated with poor prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Grunert M, Miksch J, Steinacker J, Zengerling F, Glatting G,

Keywords: NED, mCRPC, CgA, NSE, RLT, overall survival,

#3145 Reduction of serum insulin levels and diazoxide doses as an effect of PRRT in patients with severe hypoglycemia due to primary non-operative insulinoma

Introduction: Severe hypoglycaemia in a course of inoperable insulinoma may be life-threating and it is not always well controlled even by high doses of diazoxide, which in some cases cause a significant toxicity. Nowadays, other forms of effective therapy are not available - use of protein kinase inhibitors (everolimus, sunitynib) sometimes bring satisfactory effect but is often associated with the risk of serious side effects. Use of Peptide receptor radionuclide therapy (PRRT), characterized by relatively low toxicity, is not widely used.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Opalińska M

Authors: Opalinska M, Sowa-Staszczak A, Al Maraih I, Kostecka-Matyja M, Hubalewska-Dydejczyk A,

Keywords: PRRT, insulinoma, NEN,

#193 Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors

Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Cui T, Hurtig M, Li S, Veronesi G, Essaghir A,

Keywords: Ma2, blood biomarker, ELISA, autoantibody, RFS, sequential immunoprecipitation, immuno-dot-blot,

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection

Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Giandomenico V

Authors: Cui T, Elgue G, Li S, Hurtig M, Veronesi G,

Keywords: Small intestine neuroendocrine tumors, novel diagnostic biomarker, PNMA2, auto-antibodies as serum biomarker.,